Compounds > isoxazoles
Page last updated: 2024-08-21

isoxazoles and Carcinoma, Epidermoid

isoxazoles has been researched along with Carcinoma, Epidermoid in 21 studies

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19902 (9.52)18.7374
1990's2 (9.52)18.2507
2000's1 (4.76)29.6817
2010's14 (66.67)24.3611
2020's2 (9.52)2.80

Authors

AuthorsStudies
Ahn, YH; Dinkova-Kostova, AT; Proby, CM; VanHecke, GC; Zhang, Y1
Bürkel, F; Distel, LV; Faulhaber, EM; Fietkau, R; Hecht, M; Jost, T; Scheper, J; Symank, J1
Cui, H; Fu, G; Qiu, Y; Ren, A1
Abbadessa, A; Amata, E; Castilho, RM; Floresta, G; Mineo, PG; Monciino, G; Nicosia, A; Pistarà, V; Rescifina, A; Varrica, MG; Zagni, C1
Bizarro, A; Cincinelli, R; Dallavalle, S; De Cesare, M; Lima, RT; Musso, L; Sousa, D; Vasconcelos, MH; Zuco, V1
Peters, GJ1
Chen, KN; Dai, L; Dong, B; Fu, H; Kang, XZ; Liang, Z; Shen, LY; Shi, Q; Xiong, HC; Yan, WP; Yang, YB1
Azzoli, CG; Costa, DB; Gainor, JF; Heist, RS; Huberman, M; Lennes, IT; Muzikansky, A; Oxnard, GR; Piotrowska, Z; Sequist, LV; Shaw, AT1
Bouret, AM; Frances, L; Guijarro, J; Leiva-Salinas, Mdel C; Marin, I1
Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Peeters, WJ; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Wheeler, DL1
Kusewitt, DF; Lehman, AM; Nagarajan, P; Oberyszyn, TM; Pruitt, J; Riggenbach, JA; Satoskar, AR; Sielecki, T; Tober, KL1
Aleksic, T; Allen, P; Asher, R; Ashraf, SQ; Ashworth, A; Athanasou, N; Bailey, D; Bajrami, I; Blay, JY; Bodmer, WF; Feller, S; Gao, S; Han, C; Jones, TM; Kashima, T; Kigozi, A; Lord, CJ; Macaulay, VM; Machiels, JP; Middleton, MR; Ouaret, D; Schmitz, S; Thalmann, G; Upile, N; Verrill, C; Wilding, JL1
Barker, HE; Bhide, SA; Dillon, M; Harrington, KJ; Khan, AA; Kyula, JN; Mansfield, DC; McLaughlin, M; Newbold, KL; Nutting, CM; Patel, R; Pedersen, M1
Fukazawa, T; Hassan, NM; Kurio, N; Naomoto, Y; Okui, T; Sasaki, A; Shimo, T; Takaoka, M1
Fukazawa, T; Honami, T; Ibaragi, S; Mohammad Monsur Hassan, N; Naomoto, Y; Okui, T; Sasaki, A; Shimo, T; Takaoka, M1
Bao, XH; Fujiwara, T; Fukazawa, T; Hao, HF; Nakajima, M; Naomoto, Y; Sakurama, K; Takaoka, M; Takigawa, N; Yamatsuji, T1
Hedley, DW; Ruoso, P1
Bartlett, R; Bremer, EG; Finnegan, A; Kochhar, K; Mattar, T1
Blinder, L; Chong, AS; Huang, W; Mall, JW; Myers, JA; Saclarides, TJ; Shen, J; Williams, JW; Xu, X1
Billedeau, RJ; Bonaventura, BJ; Castelhano, AL; DeYoung, L; Farmer, W; Killackey, JJ; Krantz, A; Pliura, DH1
Blessing, JA; Buchsbaum, HJ; DiSaia, PJ; McGuire, WP1

Trials

1 trial(s) available for isoxazoles and Carcinoma, Epidermoid

ArticleYear
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Exons; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Prognosis; Resorcinols; Survival Rate

2018

Other Studies

20 other study(ies) available for isoxazoles and Carcinoma, Epidermoid

ArticleYear
Sulfoxythiocarbamate S-4 inhibits HSP90 in human cutaneous squamous cell carcinoma cells.
    European journal of pharmacology, 2020, Dec-15, Volume: 889

    Topics: Animals; Carcinoma, Squamous Cell; Cells, Cultured; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Keratinocytes; Mice; NIH 3T3 Cells; Resorcinols; Skin Neoplasms; Thiocarbamates

2020
Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells.
    Genes, 2021, 06-17, Volume: 12, Issue:6

    Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cells, Cultured; DNA Repair; DNA-Activated Protein Kinase; Head and Neck Neoplasms; Humans; Isoxazoles; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinolines; Triazoles; X-Rays

2021
Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.
    Molecular medicine reports, 2017, Volume: 16, Issue:6

    Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Isoxazoles; Leflunomide; Mice; Mouth Neoplasms; Xenograft Model Antitumor Assays

2017
DNA intercalators based on (1,10-phenanthrolin-2-yl)isoxazolidin-5-yl core with better growth inhibition and selectivity than cisplatin upon head and neck squamous cells carcinoma.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Intercalating Agents; Isoxazoles; Models, Molecular; Molecular Structure; Squamous Cell Carcinoma of Head and Neck; Structure-Activity Relationship

2018
Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Molecules (Basel, Switzerland), 2018, Feb-13, Volume: 23, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Isoxazoles; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyridones; raf Kinases; Signal Transduction; Skin Neoplasms; Survivin; Tumor Burden; Xenograft Model Antitumor Assays

2018
Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Nucleosides, nucleotides & nucleic acids, 2018, Volume: 37, Issue:6

    Topics: Amides; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Biphenyl Compounds; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carcinoma, Squamous Cell; Cell Line, Tumor; Dihydroorotate Dehydrogenase; Head and Neck Neoplasms; Humans; Isoxazoles; Naphthoquinones; Orotate Phosphoribosyltransferase; Oxidoreductases Acting on CH-CH Group Donors; Phosphonoacetic Acid; Purine Nucleotides; Pyrazoles; Pyrimidine Nucleotides; Ribonucleosides; Ribose

2018
The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Cancer letters, 2018, 09-28, Volume: 432

    Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cisplatin; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrazines; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
Multiple eruptive keratoacanthomas associated with leflunomide.
    Dermatology online journal, 2013, Jul-14, Volume: 19, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Isoxazoles; Keratoacanthoma; Leflunomide; Skin Neoplasms

2013
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
    Molecular cancer, 2013, Nov-05, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dasatinib; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Imidazoles; Isoxazoles; Leflunomide; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; STAT5 Transcription Factor; STAT6 Transcription Factor; Thiazoles; Tumor Suppressor Proteins

2013
MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.
    Molecular cancer research : MCR, 2014, Volume: 12, Issue:9

    Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; DNA Damage; Female; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Mice; Morpholines; Neoplasms, Radiation-Induced; Skin Neoplasms; Tumor Suppressor Protein p53; Ultraviolet Rays

2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
    Cancer research, 2014, Oct-15, Volume: 74, Issue:20

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dishevelled Proteins; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor I; Isoxazoles; Male; MAP Kinase Signaling System; Mice; Phosphoproteins; Pyrimidines; ras Proteins; Receptor, IGF Type 1; Wnt Proteins; Xenograft Model Antitumor Assays

2014
HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
    BMC cancer, 2017, 01-31, Volume: 17, Issue:1

    Topics: Animals; BRCA1 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Chromosomes; DNA Damage; DNA Fragmentation; DNA Repair; Female; Head and Neck Neoplasms; Homologous Recombination; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Protein Kinase Inhibitors; Resorcinols; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53

2017
Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Female; Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Isoxazoles; Mandibular Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Receptor, ErbB-2; Resorcinols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Current cancer drug targets, 2013, Volume: 13, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cells, Cultured; Female; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Isoxazoles; Mice; Mice, Nude; Molecular Targeted Therapy; Mouth Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Protein Kinase Inhibitors; Random Allocation; Resorcinols; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Oncology reports, 2013, Volume: 29, Issue:1

    Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Esophageal Neoplasms; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Resorcinols; RNA, Small Interfering; Tumor Cells, Cultured

2013
Inhibition of gamma-glutamyl transpeptidase activity decreases intracellular cysteine levels in cervical carcinoma.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:1

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cysteine; Enzyme Inhibitors; Female; gamma-Glutamyltransferase; Humans; Isoxazoles; Mice; Mice, SCID; Transplantation, Heterologous; Uterine Cervical Neoplasms

2004
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
    FEBS letters, 1993, Nov-15, Volume: 334, Issue:2

    Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Crotonates; ErbB Receptors; Fibroblasts; Humans; Hydroxybutyrates; Isoxazoles; KB Cells; Leflunomide; Male; Nitriles; Phosphorylation; Skin; Toluidines; Tumor Cells, Cultured

1993
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
    Biochemical pharmacology, 1999, Nov-01, Volume: 58, Issue:9

    Topics: 3T3 Cells; Adjuvants, Immunologic; Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Crotonates; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Glioma; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitriles; Phosphorylation; Pyrimidine Nucleotides; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Toluidines; Tumor Cells, Cultured; Tyrosine

1999
A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes.
    Molecular pharmacology, 1989, Volume: 35, Issue:5

    Topics: Carcinoma, Squamous Cell; Epidermis; Humans; Isoxazoles; Keratins; Proteins; Stereoisomerism; Structure-Activity Relationship; Transglutaminases; Trypan Blue; Tumor Cells, Cultured

1989
Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
    Investigational new drugs, 1986, Volume: 4, Issue:1

    Topics: Adult; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematologic Diseases; Humans; Isoxazoles; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Oxazoles

1986